Fund
Sectoral Asset Management
0 Followers
Privately held emerging life science companies developing innovative medical treatments based on…
About
Privately held emerging life science companies developing innovative medical treatments based on disruptive technologies. North America and Europe focus on biotechnology and medical technology. High velocity characteristics.
Location
Montréal, Quebec
Work
The 50 · Series B+ · Life Sciences
Stage
Series B+
Socials
- n/a
- Type
- The 50
- Stage
- Series B+
- AUM
- US$392M
- Other offices
- Geneva · Hong Kong
- Source
- The 50: Canadian VC Ecosystem Guide 2026
Investment thesis
Privately held emerging life science companies developing innovative medical treatments based on disruptive technologies. North America and Europe focus on biotechnology and medical technology. High velocity characteristics.
What makes them unique
Global sourcing with investment personnel in North America and Europe. Extensive public side experience enabling IPOs and M&A transactions.
Team
- 9 professionals, 5 partners, 3 principals with scientific, financial and company expertise
Select portfolio
Company
Aug 2026